NVIDIA recently announced that its open-source BioNeMo™ biomolecular AI framework has gained widespread adoption in the pharmaceutical field, attracting significant attention from pharmaceutical companies, biotech innovators, and AI researchers. The introduction of this framework marks the formal entry of AI-assisted drug development into the supercomputing era. As a specialized AI toolkit for biomolecular research, the BioNeMo framework offers revolutionary breakthroughs for the pharmaceutical industry. Researchers can leverage this framework to significantly enhance the computational scale of AI models, analyze massive datasets more efficiently, and achieve remarkable advancements.